GX CN MEDTECH

JPMorgan Chase Increases Stake in AliHealth by 57.04 Million Shares on May 15, Spending Approximately 246 Million HKD

DAH SING SECURITIES LOWERS ALI HEALTH TARGET PRICE FROM HKD 6 TO HKD 5.2

JD Health spends 93.26 million HKD to repurchase 2.25 million ordinary shares on May 19

Goldman Sachs: Alibaba Health's Mixed Results and Slower Growth vs JD Health Lead to Target Price Cut to HKD 4.2

HSBC cuts AliHealth profit forecasts and target price to HKD 4.5, maintains Hold rating

Citi Lowers Alibaba Health Target Price to HKD 8, Cites Heavy Investment in Innovative Drugs and AI as Short-Term Earnings Pressure

UBS Cuts Alibaba Health Earnings Forecast and Target Price, Maintains Sell Rating

JD Health and AliHealth stocks fall on GLP-1 regulatory concerns, brokers call overreaction

Citic CLSA Cuts AliHealth Target Price to 4.7, Maintains Outperform Rating

CICC Maintains Buy Rating on Ali Health with Target Price of 6.50 HKD

JD Health spends 8.9453 million HKD to repurchase 198,100 shares on May 15

Alibaba Health Releases FY2026 Results, Launches Medical AI 'Hydrogen Ion' and Unveils New Strategy

CSC Financial Maintains Buy Rating on JD Health International with Target Price of 58.28 HKD

Alibaba Health to unify B2C and O2O pharmaceutical business segments for synergy

Nomura lowers JD Health target price to HKD 67, maintains Buy rating

Alibaba Health shares drop over 4% after annual report; Citi and BofA issue ratings

ALI HEALTH released FY2026 9 Months earnings on May 14 (BJT), actual revenue HKD 28.03 B, actual EPS HKD 0.1085

ALI HEALTH released FY2026 Q3 earnings on May 14 (BJT), actual revenue HKD 9.763 B, actual EPS HKD 0.0229

ALI HEALTH released FY2026 Q4 earnings on May 14 After-Market (BJT), actual revenue HKD 9.953 B, actual EPS HKD 0.0234

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

00570

516930

588130

513120

159929

512010

510660

513060

02841

520690

516610

589720

Yesterday's closing price for China Traditional Chinese Medicine rose slightly by 1.19%, with a trading volume of approximately HKD 92 million, which is a slight increase compared to usual, reflecting the market's attention to its mid-term development prospects. The MACD daily line has not yet formed a clear strong bullish signal, but the latest dynamics in the electronic chemical pharmaceutical sector provide good visibility for it. Under the influence of news, the government's support for the traditional Chinese medicine industry is evident. With the continuous expansion of domestic healthcare demand and the increasing awareness of healthy living, the demand potential in the traditional Chinese medicine market is gradually being released. The company is further enhancing its market competitiveness through continuous research and development, innovation initiatives, and the expansion of its market network. Technically, the stock price trend remains stable above the mid-line trend level, reflecting that short-term positions are still primarily focused on position management. As market sentiment gradually recovers, if downward resistance diminishes, we can expect more significant liquidity changes and a positive drive for the market to refocus on the traditional Chinese medicine concept. The short-term trend is positively referenced, especially with the support of favorable industry prospects, traditional Chinese medicine concept stocks are not afraid of short-term market fluctuations. Caution is needed regarding the impact of the board's substantive decisions on stock prices, as well as the potential chain reaction from important economic indicators exceeding expectations. This article provides only technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances

Technical Forecast

TRAD CHI MED

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Universal 800 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

GF CSI All Share Health Care ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai CSI Bio-medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI HK Equities Medical and Health Integration ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

Guotai SSE STAR Brand Name Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Pre-market trend | China Traditional Chinese Medicine (0570.HK) slightly warmed up on May 7, is there a hint of spring for the TCM concept?

159837

516820

588250

The General Office of the State Council issued "Several Opinions on Improving the Price Formation Mechanism for Pharmaceuticals," proposing to optimize the initial pricing mechanism for newly launched innovative drugs, improve the price formation mechanism for centralized bulk purchasing of pharmaceuticals, encourage various entities to participate in price formation, promote diversified payment and reasonable price formation for innovative drugs, and strengthen measures to ensure supply and stabilize prices for shortage drugs. The opinions also emphasize strengthening pharmaceutical price governance, implementing price risk early warning, preventing irrational bidding behavior, supporting the high-quality development of the pharmaceutical industry, and ensuring that the public has access to high-quality and reasonably priced medications

AASTOCKS

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

iShares US Pharma

ChinaAMC CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Mainland China releases a sound drug pricing formation mechanism to optimize the initial pricing mechanism for innovative drugs and others

01515

China Resources Medical Profit Slips as Revenue Declines but Dividends Edge Higher

Tip Ranks

CR MEDICAL

China Resources Medical Profit Slips as Revenue Declines but Dividends Edge Higher

TRAD CHI MED announced its performance for the fiscal year 2025, with a revenue of 14.745 billion RMB, a year-on-year decrease of 10.7%. It recorded a loss of 342 million RMB, compared to a net profit of 54.07 million RMB in the previous year, turning from profit to loss; the loss per share is 6.79 cents. No final dividend will be distributed

"Performance" TRAD CHI MED reported a full-year loss of 342 million RMB, turning from profit to loss

300015

The "Implementation Rules for the Supervision and Administration of Medical Security Fund Usage" were passed on February 12, 2026, and will take effect on April 1, 2026. The rules require medical security handling agencies to suspend the settlement and payment of expenses for designated medical institutions suspected of defrauding the medical security fund at the request of the medical security administrative department, until they cooperate with the investigation. During the suspension period, if the medical expenses are confirmed to be fraudulent after investigation, they will be handled according to relevant regulations; if not, they will be settled according to regulations after the suspension is lifted

Wallstreetcn

Aier

The "Implementation Rules for the Supervision and Administration of the Use of Medical Security Fund" have been announced and will take effect on April 1

GX CN MEDTECH(02841.HK)

Pre-market trend | China Traditional Chinese Medicine (0570.HK) slightly warmed up on May 7, is there a hint of spring for the TCM concept?

Mainland China releases a sound drug pricing formation mechanism to optimize the initial pricing mechanism for innovative drugs and others

China Resources Medical Profit Slips as Revenue Declines but Dividends Edge Higher

"Performance" TRAD CHI MED reported a full-year loss of 342 million RMB, turning from profit to loss

The "Implementation Rules for the Supervision and Administration of the Use of Medical Security Fund" have been announced and will take effect on April 1